nasal polyps Archives -

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment

FDA says no to AZ’s Fasenra for nasal polyp indication

https://pharmaphorum.com/news/fda-says-no-to-azs-fasenra-for-nasal-polyp-indication/

Amgen and partner AstraZeneca have said their recently filed severe asthma drug tezepelumab has shown impressive results in

Amgen builds case for severe asthma drug tezepelumab

https://pharmaphorum.com/news/amgen-builds-case-for-severe-asthma-drug-tezepelumab/

Sanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps

Sanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polyps

https://pharmaphorum.com/news/dupixent-on-notice-as-fda-reviews-gsks-nucala-for-nasal-polyps/

AstraZeneca’s Fasenra (benralizumab) injected drug cuts the size of nasal polyps and nasal blockage in patients with chronic

AZ’s Fasenra on target in nasal polyps trial

https://pharmaphorum.com/news/azs-fasenra-on-target-in-nasal-polyps-trial/

GlaxoSmithKline is eyeing another indication for its Nucala (mepolizumab) biologic drug after a phase 3 trial in inflammation

GSK eyes nasal polyps use for Nucala after trial success

https://pharmaphorum.com/news/gsk-eyes-nasal-polyps-use-for-nucala-after-trial-success/

Regeneron and Sanofi’s immunology drug Dupixent has been approved for a third indication in Europe, adding the treatment

Regeneron/Sanofi get EU okay for Dupixent in “asthma of the sinuses”

https://pharmaphorum.com/news/regeneron-sanofi-get-eu-okay-for-dupixent-in-asthma-of-the-sinuses/

Trials of Sanofi and Regeneron’s drug Dupixent (dupilumab) have shown positive results for treating patients suffering from chronic

Sanofi/Regeneron’s Dupixent could be first biologic approved for nasal polyps

https://pharmaphorum.com/news/sanofi-regenerons-dupixent-could-be-first-biologic-approved-for-nasal-polyps/

nasal polyps